Feasibility of virtual Alzheimer's biomarker disclosure: Findings from an observational cohort

IF 4.9 Q1 CLINICAL NEUROLOGY

Alzheimer''s and Dementia: Translational Research and Clinical Interventions Pub Date : 2023-07-29 DOI:10.1002/trc2.12413

Claire M. Erickson, Nathaniel A. Chin, Hannah L. Rosario, Amanda Peterson, Sterling C. Johnson, Lindsay R. Clark

引用次数: 1

Abstract

Increased availability of Alzheimer's disease (AD) biomarker tests provides older adults with opportunities to seek out and learn results. We evaluated the feasibility of virtually returning AD biomarker results.

Abstract Image

查看原文本刊更多论文

虚拟阿尔茨海默病生物标志物披露的可行性:来自观察队列的发现

阿尔茨海默病(AD)生物标志物测试的增加为老年人提供了寻求和了解结果的机会。我们评估了虚拟返回AD生物标志物结果的可行性。方法:训练有素的临床医生披露淀粉样正电子发射断层扫描(PET)结果，并通过电视视频向已参加AD研究的认知功能正常的参与者提供痴呆风险降低咨询(n = 99;平均年龄±SD: 72.0±4.8;67%的女性;95%的白人;淀粉样蛋白升高28%)。结果我们的研究显示了可接受的保留率(93%)、依从性(98%)、依从性(98%)、临床医生能力(97%)、教育理解(测验得分14/15)和虚拟就诊功能(评分9.4/10)。抑郁、焦虑和自杀倾向仍然很低，且淀粉样蛋白结果没有差异。淀粉样蛋白PET结果对认知未受损的研究参与者的虚拟返回是可行的，并且不会导致心理症状的增加。一些参与者面临的技术障碍突出了灵活性的必要性。这些发现支持在AD生物标志物披露中使用电视，尽管我们的研究样本和设计在推广方面存在重要的局限性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer''s and Dementia: Translational Research and Clinical Interventions Medicine-Psychiatry and Mental Health

CiteScore

10.10

自引率

2.10%

发文量

134

审稿时长

10 weeks

期刊介绍： Alzheimer''s & Dementia: Translational Research & Clinical Interventions (TRCI) is a peer-reviewed, open access,journal from the Alzheimer''s Association®. The journal seeks to bridge the full scope of explorations between basic research on drug discovery and clinical studies, validating putative therapies for aging-related chronic brain conditions that affect cognition, motor functions, and other behavioral or clinical symptoms associated with all forms dementia and Alzheimer''s disease. The journal will publish findings from diverse domains of research and disciplines to accelerate the conversion of abstract facts into practical knowledge: specifically, to translate what is learned at the bench into bedside applications. The journal seeks to publish articles that go beyond a singular emphasis on either basic drug discovery research or clinical research. Rather, an important theme of articles will be the linkages between and among the various discrete steps in the complex continuum of therapy development. For rapid communication among a multidisciplinary research audience involving the range of therapeutic interventions, TRCI will consider only original contributions that include feature length research articles, systematic reviews, meta-analyses, brief reports, narrative reviews, commentaries, letters, perspectives, and research news that would advance wide range of interventions to ameliorate symptoms or alter the progression of chronic neurocognitive disorders such as dementia and Alzheimer''s disease. The journal will publish on topics related to medicine, geriatrics, neuroscience, neurophysiology, neurology, psychiatry, clinical psychology, bioinformatics, pharmaco-genetics, regulatory issues, health economics, pharmacoeconomics, and public health policy as these apply to preclinical and clinical research on therapeutics.